Business
Daré Bioscience Reports Full Year 2020 Financial Results and Provides a Company Update
Conference Call and Webcast Today at 4:30 p.m. Eastern Time SAN DIEGO, March 30, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in
About this update from Dare Bioscience, Inc.
[{"type":"text","content":"Conference Call and Webcast Today at 4:30 p.m. Eastern Time\nSAN DIEGO, March 30, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2020 and provided a company update. “Despite the unique challenges posed during 2020, we achieved two important corporate firsts in 2020. We started the year in January by announcing our first commercial partnership agreement, with Bayer for Ovaprene® commercialization rights. We believe that this partnership not only validates the Ovaprene commercial opportunity and allows Daré to benefit from Bayer’s expertise in development, regulatory affairs and commercialization of first-in-category contraceptive products for women, but, with up to $310 million in commercial milestone payments, plus double-digit, tiered royalties on net sales, that it will also provide capital to support broader portfolio objectives. Then, we ended the year in December with the completion of our first portfolio Phase 3 study – specifically, we announced positive topline data from the DARE-BVFREE Phase 3 study of DARE-BV1 for the treatment of bacterial vaginosis, positioning Daré for our first NDA submission,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “The advances in 2020 across the portfolio set the stage for meaningful portfolio objectives in 2021.” 2021 Key Portfolio Objectives DARE-BV1: New Drug Application (NDA) submission and strategic commercialization agreement.Sildenafil Cream, 3.6%: Phase 2b clinical study commencement and topline data.Ovaprene: Investigational Device Exemption (IDE) submission.DARE-HRT1: Phase 1 clinical study topline data.DARE-VVA1: Initiation of Phase 1 clinical study. 2020 Portfolio Accomplishments and Management Expectations for 2021 DARE-BV1: Daré solution: Novel, investigational thermosetting bioadhesive hydrogel formulated with clindamycin phosphate 2% as a first-line, single-administration treatment for bacterial vaginosis.Successful completion of the DARE-BVFREE Phase 3 clinical study in 4Q 2020.Phase 3 study results: A single dose of DARE-BV1 delivered statistically significant efficacy (76.0% clinical cure rate at Day 7-14 and 70.2% at Day 21-30 (primary endpoint) in the modified intent-to-treat population). The study demonstrated DARE-BV1’s poten...